Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice

Endocrinology

Volumn 153, Issue 1, 2012, Pages 17-28

  Kuroshima, Shinichiro ^a,b   Go, Virginia Arlene A ^a   Yamashita, Junro ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; CALCIUM; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE REMODELING; CALCIUM BLOOD LEVEL; CELL ADHESION; CONNECTIVE TISSUE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME BLOOD LEVEL; EPITHELIUM; FEMUR; FLOW CYTOMETRY; INFLAMMATORY INFILTRATE; JAW OSTEONECROSIS; LONG TERM CARE; MALE; MAXILLA; MICRO-COMPUTED TOMOGRAPHY; MONONUCLEAR CELL; MORPHOMETRICS; MOUSE; MOUTH INJURY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; STEM CELL; TRABECULAR BONE; WOUND HEALING; WOUND HEALING IMPAIRMENT;

ACID PHOSPHATASE; ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CELL ADHESION; DIPHOSPHONATES; IMIDAZOLES; ISOENZYMES; MALE; MAXILLA; MICE; MICE, INBRED C57BL; MOUTH MUCOSA; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOCLASTS; TIBIA; TIME FACTORS; WOUND HEALING; X-RAY MICROTOMOGRAPHY;

EID: 84455160821     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1439     Document Type: Article

References (59)

1. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G 2007 Endocrine regulation of energy metabolism by the skeleton. Cell 130:456-469 (Pubitemid 47208519)
2. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T 2006 Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774 (Pubitemid 44949607)
3. Kiesel JR, Buchwald ZS, Aurora R 2009 Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells. J Immunol 182:5477-5487
4. Herman S,Müller RB, Krönke G, Zwerina J, Redlich K, Hueber AJ, Gelse H, Neumann E, Müller-Ladner U, Schett G 2008 Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. Arthritis Rheum 58:3041-3050
5. Shu L, Ji J, Zhu Q, Cao G, Karaplis A, Pollak MR, Brown E, Goltzman D, Miao D 2011 The calcium-sensing receptor mediates bone turnover induced by dietary calcium and parathyroid hormone in neonates. J Bone Miner Res 26:1057-1071
6. Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, Tesio M, Samstein RM, Goichberg P, Spiegel A, Elson A, Lapidot T 2006 Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 12:657-664 (Pubitemid 43865234)
7. Yao Z, Xing L, Qin C, Schwarz EM, Boyce BF 2008 Osteoclast precursor interaction with bone matrix induces osteoclast formation directly by an interleukin-1-mediated autocrine mechanism. J Biol Chem 283:9917-9924
8. Yamashita J, Koi K, Yang DY, McCauley LK 2011 Effect of zoledronate on oral wound healing in rats. Clin Cancer Res 17:1405-1414
9. Aghaloo TL, Kang B, Sung EC, Shoff M, Ronconi M, Gotcher JE, Bezouglaia O, Dry SM, Tetradis S 2011 Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J Bone Miner Res 26:1871-1882
10. Cheung MS, Glorieux FH, Rauch F 2009 Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate. J Bone Miner Res 24:669-674
11. Weinstein RS, Roberson PK, Manolagas SC 2009 Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 360:53-62
12. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKeeMD,Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E 2007 Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral research. J Bone Miner Res 22:1479-1491 (Pubitemid 351229318)
13. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG 1993 Clinical pharmacology of alendronate sodium. Osteoporos Int 3(Suppl 3):S13-S16
14. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K 2009 Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356-5362
15. Barasch A, Cunha-Cruz J, Curro FA, Hujoel P, Sung AH, Vena D, Voinea-Griffin AE, Beadnell S, Craig RG, DeRouen T, Desaranayake A, Gilbert A, Gilbert GH, Goldberg K, Hauley R, Hashimoto M, Holmes J, Latzke B, Leroux B, Lindblad A, Richman J, Safford M, Ship J, Thompson VP, Williams OD, Yin W 2011 Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res 90:439-444
16. Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, Green J, Van Marck E, Van Camp B, Vanderkerken K 2003 Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 18:482-492 (Pubitemid 36241065)
17. Kikuiri T, Kim I, Yamaza T, Akiyama K, Zhang Q, Li Y, Chen C, Chen W, Wang S, Le AD, Shi S 2010 Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res 25:1668-1679
18. Kubek DJ, Burr DB, Allen MR 2010 Ovariectomy stimulates and bisphosphonates inhibit intracortical remodeling in the mouse mandible. Orthod Craniofac Res 13:214-222
19. Everts V, Delaissé JM, Korper W, Jansen DC, Tigchelaar-Gutter W, Saftig P, Beertsen W 2002 The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res 17:77-90 (Pubitemid 33150999)
20. Taylor RD 1966 Modification of the Brown and Brenn gram stain for the differential staining of gram-positive and gram-negative bacteria in tissue sections. Am J Clin Pathol 46:472-474
21. Hao Q, Su H, Marchuk DA, Rola R, Wang Y, Liu W, Young WL, Yang GY 2008 Increased tissue perfusion promotes capillary dysplasia in the ALK1-deficient mouse brain following VEGF stimulation. Am J Physiol Heart Circ Physiol 295:H2250-H2256
22. MacDonald IC, Aharinejad S, Schmidt EE, Groom AC 1995 Luminal constrictions due to endothelial cells in capillaries of mouse exocrine pancreas. Microvasc Res 49:64-77
23. Dobson KR, Reading L, Haberey M, Marine X, Scutt A 1999 Centrifugal isolation of bone marrow from bone: an improved method for the recovery and quantitation of bone marrow osteoprogenitor cells from rat tibiae and femurae. Calcif Tissue Int 65:411-413 (Pubitemid 29514082)
24. Ferguson VL, Ayers RA, Bateman TA, Simske SJ 2003 Bone development and age-related bone loss in male C57BL/6J mice. Bone 33:387-398 (Pubitemid 37107464)
25. Halloran BP, Ferguson VL, Simske SJ, Burghardt A, Venton LL, Majumdar S 2002 Changes in bone structure and mass with advancing age in the male C57BL/6J mouse. J Bone Miner Res 17: 1044-1050 (Pubitemid 34535142)
26. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199 (Pubitemid 38339363)
27. Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W 1996 Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 18:141-150 (Pubitemid 26092594)
28. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, Mc-Closkey EV, Beneton MN, Gertz BJ, Sciberras DG, Holland SD, Orgee J, Coombes GM, Rogers SR, Porras AG 1997 Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12:1700-1707 (Pubitemid 27422371)
29. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ 2000 Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15:1467-1476 (Pubitemid 30484516)
30. Coxon FP, Thompson K, Rogers MJ 2006 Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 6:307-312 (Pubitemid 43670914)
31. Halasy-Nagy JM, Rodan GA, Reszka AA 2001 Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 29:553-559 (Pubitemid 33124298)
32. Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J 2011 Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49:34-41
33. Janckila AJ, Neustadt DH, Yam LT 2008 Significance of serum TRACP in rheumatoid arthritis. J Bone Miner Res 23:1287-1295 (Pubitemid 352040183)
34. Rissanen JP, Suominen MI, Peng Z, Halleen JM 2008 Secreted tartrate- resistant acid phosphatase 5b is a marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int 82:108-115
35. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LK 2005 Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146:1727-1736 (Pubitemid 40396881)
36. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D 2009 Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 150:4835-4845
37. Chang J, Wang Z, Tang E, Fan Z, McCauley L, Franceschi R, Guan K, Krebsbach PH, Wang CY 2009 Inhibition of osteoblastic bone formation by nuclear factor-≲καππα∀B. Nat Med 15:682-689
38. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK 2000 Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15:1337-1345 (Pubitemid 30413866)
39. Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimaki T, Schmidt- Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievanen H, Vuori I, Vaananen HK, Halleen JM 2005 Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20:1804-1812 (Pubitemid 41361881)
40. Shidara K, Inaba M, Okuno S, Yamada S, Kumeda Y, Imanishi Y, Yamakawa T, Ishimura E, Nishizawa Y 2008 Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int 82:278-287
41. Chao TY, Yu JC, Ku CH, Chen MM, Lee SH, Janckila AJ, Yam LT 2005 Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients. Clin Cancer Res 11:544-550 (Pubitemid 40116878)
42. Shen Z, Crotti TN, McHugh KP, Matsuzaki K, Gravallese EM, Bierbaum BE, Goldring SR 2006 The role played by cell-substrate interactions in the pathogenesis of osteoclast-mediated peri-implant osteolysis. Arthritis Res Ther 8:R70
43. Zhu XW, Price NM, Gilman RH, Recarvarren S, Friedland JS 2007 Multinucleate giant cells release functionally unopposed matrix metalloproteinase-9 in vitro and in vivo. J Infect Dis 196:1076-1079 (Pubitemid 47580303)
44. Coury F, Annels N, Rivollier A, Olsson S, Santoro A, Speziani C, Azocar O, Flacher M, Djebali S, Tebib J, Brytting M, Egeler RM, Rabourdin-Combe C, Henter JI, Arico M, Delprat C 2008 Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med 14:81-87
45. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN 2008 Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826-836 (Pubitemid 351768801)
46. Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z, Patrikidou A, Triaridis S 2008 Bisphosphonaterelated osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 26:4634-4638
47. Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K 1996 Aerosol insulin induces regulatory CD8 γδ T cells that prevent murine insulin-dependent diabetes. J Exp Med 184:2167-2174
48. Holoshitz J 1999 Activation of γδ T cells by mycobacterial antigens in rheumatoid arthritis. Microbes Infect 1:197-202
49. Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS, O'Fallon WM, Riggs BL 1994 Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 4:320-322
50. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clézardin P 2002 Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538-6544 (Pubitemid 35364119)
51. Bäuerle T, Merz M, Komljenovic D, Zwick S, Semmler W 2010 Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study. Clin Cancer Res 16:3215-3225
52. Deckers MM, Van Beek ER, Van Der Pluijm G, Wetterwald A, Van Der Wee-Pals L, Cecchini MG, Papapoulos SE, Löwik CW 2002 Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. J Bone Miner Res 17: 998-1007
53. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E 2008 Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases. Med Oncol 25:346-349
54. Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM 2005 The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am 87:2155-2159
55. Ramachandran M, Ward K, Brown RR, Munns CF, Cowell CT, Little DG 2007 Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents. J Bone Joint Surg Am 89:1727-1734 (Pubitemid 47229879)
56. Rozental TD, Vazquez MA, Chacko AT, Ayogu N, Bouxsein ML 2009 Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg Am 34:595-602
57. Huang RC, Khan SN, Sandhu HS, Metzl JA, Cammisa Jr FP, Zheng F, Sama AA, Lane JM 2005 Alendronate inhibits spine fusion in a rat model. Spine 30:2516-2522 (Pubitemid 41669087)
58. Kobayashi Y, Hiraga T, Ueda A, Wang L, Matsumoto-Nakano M, Hata K, Yatani H, Yoneda T 2010 Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab 28:165-175
59. Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P 2010 Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122:181-188